Ads
related to: abbvie inc
Search results
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Zacks via Yahoo Finance· 7 hours agoAbbVie Inc. ABBV reported adjusted earnings of $2.31 per share for first-quarter 2024, beating the...
AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges
GuruFocus.com via Yahoo Finance· 10 hours agoOn April 26, 2024, AbbVie Inc (NYSE:ABBV) released its 8-K filing, detailing the financial outcomes...
AbbVie’s first-quarter results top expectations as arthritis drugs fuel growth
Market Watch· 12 hours agoAbbVie Inc. on Friday reported first-quarter results that beat expectations, even as sales of...
AbbVie: Q1 Earnings Snapshot
Associated Press Finance via Yahoo Finance· 12 hours agoNORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported first-quarter earnings of $1.37 billion. On a per-share basis ...
AbbVie Lifts 2024 Forecast as Newer Drugs Replace Humira Losses
Bloomberg· 12 hours agoAbbVie Inc. lifted its full-year profit guidance as newer anti-inflammatory treatments like Rinvoq...
Analyst Report: AbbVie Inc.
Morningstar Research via Yahoo Finance· 6 hours agoAbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early ...
AbbVie lifts profit forecast after Skyrizi sales beat expectations
Reuters· 11 hours ago, opens new tab raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the ...
AbbVie Lifts FY24 Outlook After Higher Q1 Results - Update
RTT News· 11 hours agoAbbVie Inc. (ABBV), while announcing higher first-quarter earnings, on Friday raised its outlook for fiscal 2024. In pre-market activity on the NYSE, AbbVie shares were gaining around 1.
Abbvie Inc (ABBV) Shares Up Despite Recent Market Volatility – News Heater
NewsHeater· 5 days agoThe stock price of Abbvie Inc (NYSE: ABBV) has surged by 1.06 when compared to previous closing price of 164.66, but the company has seen a 2.54% gain in ...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 1 day agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
